These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

146 related items for PubMed ID: 7507165

  • 1. Design and synthesis of novel cyclic RGD-containing peptides as highly potent and selective integrin alpha IIb beta 3 antagonists.
    Cheng S, Craig WS, Mullen D, Tschopp JF, Dixon D, Pierschbacher MD.
    J Med Chem; 1994 Jan 07; 37(1):1-8. PubMed ID: 7507165
    [Abstract] [Full Text] [Related]

  • 2. Preferential antagonism of the interactions of the integrin alpha IIb beta 3 with immobilized glycoprotein ligands by snake-venom RGD (Arg-Gly-Asp) proteins. Evidence supporting a functional role for the amino acid residues flanking the tripeptide RGD in determining the inhibitory properties of snake-venom RGD proteins.
    Lu X, Williams JA, Deadman JJ, Salmon GP, Kakkar VV, Wilkinson JM, Baruch D, Authi KS, Rahman S.
    Biochem J; 1994 Dec 15; 304 ( Pt 3)(Pt 3):929-36. PubMed ID: 7529494
    [Abstract] [Full Text] [Related]

  • 3. The integrin alpha IIb beta 3 contains distinct and interacting binding sites for snake-venom RGD (Arg-Gly-Asp) proteins. Evidence that the receptor-binding characteristics of snake-venom RGD proteins are related to the amino acid environment flanking the sequence RGD.
    Rahman S, Lu X, Kakkar VV, Authi KS.
    Biochem J; 1995 Nov 15; 312 ( Pt 1)(Pt 1):223-32. PubMed ID: 7492316
    [Abstract] [Full Text] [Related]

  • 4. Design of potent and specific integrin antagonists. Peptide antagonists with high specificity for glycoprotein IIb-IIIa.
    Scarborough RM, Naughton MA, Teng W, Rose JW, Phillips DR, Nannizzi L, Arfsten A, Campbell AM, Charo IF.
    J Biol Chem; 1993 Jan 15; 268(2):1066-73. PubMed ID: 8419315
    [Abstract] [Full Text] [Related]

  • 5. Thrombus imaging using technetium-99m-labeled high-potency GPIIb/IIIa receptor antagonists. Chemistry and initial biological studies.
    Pearson DA, Lister-James, McBride WJ, Wilson DM, Martel LJ, Civitello ER, Dean RT.
    J Med Chem; 1996 Mar 29; 39(7):1372-82. PubMed ID: 8691467
    [Abstract] [Full Text] [Related]

  • 6. Comparison of disintegrins with limited variation in the RGD loop in their binding to purified integrins alpha IIb beta 3, alpha V beta 3 and alpha 5 beta 1 and in cell adhesion inhibition.
    Pfaff M, McLane MA, Beviglia L, Niewiarowski S, Timpl R.
    Cell Adhes Commun; 1994 Dec 29; 2(6):491-501. PubMed ID: 7538018
    [Abstract] [Full Text] [Related]

  • 7. Comparative specificity of platelet alpha(IIb)beta(3) integrin antagonists.
    Thibault G, Tardif P, Lapalme G.
    J Pharmacol Exp Ther; 2001 Mar 29; 296(3):690-6. PubMed ID: 11181894
    [Abstract] [Full Text] [Related]

  • 8. A three-residue cyclic scaffold of non-RGD containing peptide analogues as platelet aggregation inhibitors: design, synthesis, and structure--function relationships.
    Stavrakoudis A, Bizos G, Eleftheriadis D, Kouki A, Panou-Pomonis E, Sakarellos-Daitsiotis M, Sakarellos C, Tsoukatos D, Tsikaris V.
    Biopolymers; 2001 Mar 29; 56(1):20-6. PubMed ID: 11582574
    [Abstract] [Full Text] [Related]

  • 9. Pharmacophore refinement of gpIIb/IIIa antagonists based on comparative studies of antiadhesive cyclic and acyclic RGD peptides.
    Müller G, Gurrath M, Kessler H.
    J Comput Aided Mol Des; 1994 Dec 29; 8(6):709-30. PubMed ID: 7738606
    [Abstract] [Full Text] [Related]

  • 10. Platelet alpha IIb beta 3: a pharmacological integrin as a target to design new molecules with antithrombotic activity.
    Marguerie G, Jarrin A, Andrieux A.
    Nouv Rev Fr Hematol (1978); 1993 Jun 29; 35(3):253-4. PubMed ID: 7687771
    [No Abstract] [Full Text] [Related]

  • 11. Selection and structure of ion-selective ligands for platelet integrin alpha IIb(beta) 3.
    Smith JW, Le Calvez H, Parra-Gessert L, Preece NE, Jia X, Assa-Munt N.
    J Biol Chem; 2002 Mar 22; 277(12):10298-305. PubMed ID: 11748219
    [Abstract] [Full Text] [Related]

  • 12. Inhibition of integrin-mediated platelet aggregation, fibrinogen-binding, and interactions with extracellular matrix by nonpeptidic mimetics of Arg-Gly-Asp.
    Varon D, Lider O, Dardik R, Shenkman B, Alon R, Hershkoviz R, Kapustina G, Savion N, Martinowitz U, Greenspoon N.
    Thromb Haemost; 1993 Dec 20; 70(6):1030-6. PubMed ID: 8165596
    [Abstract] [Full Text] [Related]

  • 13. Selective alpha IIb beta 3 receptor blockage with peptide TP9201 prevents platelet uptake on Dacron vascular grafts without significant effect on bleeding time.
    Mazur C, Tschopp JF, Faliakou EC, Gould KE, Diehl JT, Pierschbacher MD, Connolly RJ.
    J Lab Clin Med; 1994 Oct 20; 124(4):589-99. PubMed ID: 7523555
    [Abstract] [Full Text] [Related]

  • 14. Inhibition of platelet aggregation by grafting RGD and KGD sequences on the structural scaffold of small disulfide-rich proteins.
    Reiss S, Sieber M, Oberle V, Wentzel A, Spangenberg P, Claus R, Kolmar H, Lösche W.
    Platelets; 2006 May 20; 17(3):153-7. PubMed ID: 16702041
    [Abstract] [Full Text] [Related]

  • 15. Solid-phase synthesis of cyclic RGD-furanoid sugar amino acid peptides as integrin inhibitors.
    van Well RM, Overkleeft HS, van der Marel GA, Bruss D, Thibault G, de Groot PG, van Boom JH, Overhand M.
    Bioorg Med Chem Lett; 2003 Feb 10; 13(3):331-4. PubMed ID: 12565923
    [Abstract] [Full Text] [Related]

  • 16. Use of conformationally restricted benzamidines as arginine surrogates in the design of platelet GPIIb-IIIa receptor antagonists.
    Sall DJ, Arfsten AE, Bastian JA, Denney ML, Harms CS, McCowan JR, Morin JM, Rose JW, Scarborough RM, Smyth MS, Um SL, Utterback BG, Vasileff RT, Wikel JH, Wyss VL, Jakubowski JA.
    J Med Chem; 1997 Aug 29; 40(18):2843-57. PubMed ID: 9288166
    [Abstract] [Full Text] [Related]

  • 17. Concept and progress in the development of RGD-containing peptide pharmaceuticals.
    Craig WS, Cheng S, Mullen DG, Blevitt J, Pierschbacher MD.
    Biopolymers; 1995 Aug 29; 37(2):157-75. PubMed ID: 7534489
    [Abstract] [Full Text] [Related]

  • 18. Human platelet activation is inhibited by the occupancy of glycoprotein IIb/IIIa receptor.
    Padoin E, Alexandre A, Cavallini L, Polverino de Laureto P, Rao GH, Doni MG.
    Arch Biochem Biophys; 1996 Sep 15; 333(2):407-13. PubMed ID: 8809080
    [Abstract] [Full Text] [Related]

  • 19. Low molecular weight, non-peptide fibrinogen receptor antagonists.
    Alig L, Edenhofer A, Hadváry P, Hürzeler M, Knopp D, Müller M, Steiner B, Trzeciak A, Weller T.
    J Med Chem; 1992 Nov 13; 35(23):4393-407. PubMed ID: 1447740
    [Abstract] [Full Text] [Related]

  • 20. Solution structure of a cyclic RGD peptide that inhibits platelet aggregation.
    Jois SD, Tambunan US, Chakrabarti S, Siahaan TJ.
    J Biomol Struct Dyn; 1996 Aug 13; 14(1):1-11. PubMed ID: 8877556
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.